If approved, garadacimab will be the first and only once-monthly treatment inhibiting factor XIIa to prevent attacks in HAE patients – a community CSL has been serving for more than 40 years MARBURG, Germany, Dec. 13, 2024 /PRNewswire/ — Global biotechnology leader CSL (ASX:CSL;…